Immunotherapy harnesses the immune system to recognize and destroy cancer cells. This review focuses on the different agents that are currently approved in genitourinary cancers and highlights promising therapeutic strategies in this field. The clinical data generated in advanced urological cancer, advanced renal cell carcinoma (RCC) and metastatic prostate cancer will be discussed
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
